SCHEMBL6772589

SCHEMBL6772589

CCN/C(=N\C#N)Nc1cccc(C(=O)OC)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TP53 P04637 1/20 0.50
NPC1 O15118 3/20 0.49
HPGD P15428 1/20 0.47
MAPT P10636 5/20 0.47
CASR P41180 1/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
HTT P42858 1/20 0.45
POLB P06746 1/20 0.45
GPR17 Q13304 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772591 1.00 RAB9A (0.51) RAB9AALDH1A1SMN1; SMN2TP53NPC1
SCHEMBL6776099 0.88 NR1H4 (0.49) RAB9AALDH1A1SMN1; SMN2NPC1CASR
SCHEMBL6776098 0.88 NR1H4 (0.49) RAB9AALDH1A1SMN1; SMN2NPC1CASR
SCHEMBL6773280 0.86 ALDH1A1 (0.55) RAB9AALDH1A1SMN1; SMN2TP53NPC1
SCHEMBL6773278 0.86 ALDH1A1 (0.55) RAB9AALDH1A1SMN1; SMN2TP53NPC1
SCHEMBL6772415 0.86 RAB9A (0.59) RAB9AALDH1A1SMN1; SMN2TP53NPC1
SCHEMBL6772413 0.86 RAB9A (0.59) RAB9AALDH1A1SMN1; SMN2TP53NPC1
SCHEMBL6773990 0.82 RAB9A (0.56) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL6773986 0.82 RAB9A (0.56) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL6783215 0.81 TSHR (0.57) RAB9AALDH1A1SMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed